A patient with hypereosinophilic syndrome that manifested with acquired hemophilia and elevated IgG4: a case report by Nagao, Yoshiro et al.
CASE REPORT Open Access
A patient with hypereosinophilic syndrome that
manifested with acquired hemophilia and
elevated IgG4: a case report
Yoshiro Nagao
1*, Hiromi Yamanaka
2 and Hiromasa Harada
1
Abstract
Introduction: Hypereosinophilic syndrome is defined as a prolonged state (more than six months) of eosinophilia
(greater than 1500 cells/μL), without an apparent etiology and with end-organ damage. Hypereosinophilic
syndrome can cause coagulation abnormalities. Among Hypereosinophilic syndrome types, the lymphocytic variant
(lymphocytic Hypereosinophilic syndrome) is derived from a monoclonal proliferation of T lymphocytes. Here, we
describe the case of a patient with lymphocytic Hypereosinophilic syndrome who presented with a coagulation
abnormality. To the best of our knowledge, this is the first such report including a detailed clinical picture and
temporal cytokine profile.
Case presentation: A 77-year-old Japanese man presented to our facility with massive hematuria and
hypereosinophilia (greater than 2600 cells/μl). His eosinophilia first appeared five years earlier when he developed
femoral artery occlusion. He manifested with multiple hematomas and prolonged activated partial thromboplastin
time. His IgG4 level was remarkably elevated (greater than 2000 mg/dL). Polymerase chain reaction tests of
peripheral blood and bone marrow identified lymphocytic Hypereosinophilic syndrome. His prolonged activated
partial thromboplastin time was found to be due to acquired hemophilia. Glucocorticoids suppressed both the
hypereosinophilia and coagulation abnormality. However, tapering of glucocorticoids led to a relapse of the
coagulation abnormality alone, without eosinophilia. Tumor necrosis factor a, interleukin-5, and/or eotaxin-3 may
have caused the hypereosinophilia, and interleukin-10 was correlated with the coagulation abnormality.
Conclusions: To the best of our knowledge, this is the first case in which lymphocytic Hypereosinophilic syndrome
and IgG4-related disease have overlapped. In addition, our patient is only the second case of hypereosinophilic
disease that manifested with acquired hemophilia. Our patient relapsed with the coagulation abnormality alone,
without eosinophilia. This report shows that the link between eosinophilia, IgG4, and clinical manifestations is not
simple and provides useful insight into the immunopathology of Hypereosinophilic syndrome and IgG4-related
disease.
Introduction
Hypereosinophilic syndrome (HES) was originally pro-
posed as a state of (i) blood eosinophilia with an abso-
lute eosinophil count greater than 1500 cells/μLa n d
persisting for more than six months, (ii) without an
apparent etiology (for example, parasitic infection or
allergic disease), and (iii) with eosinophil-mediated
organ dysfunction [1]. Currently, HES is classified based
on etiology [2]. For example, the lymphocytic variant (L-
HES) is derived from a monoclonal proliferation of T
lymphocytes. T cell clones identified in L-HES often
express aberrant immunophenotypes (for example, CD3-
CD4+, CD3+CD4-CD8-, CD4+CD7-, CD16+CD56+)
[3-6], although no aberrancy has been identified in
many patients with L-HES [7]. In contrast, the myelo-
proliferative variant (M-HES) is characterized by emer-
gence of fusion genes (for example, PDGFRa, PDGFRb,
and FGFR1) originating from a chromosomal transloca-
tion in 4q12, 5q33, and 8p11, respectively [8]. HES
affects not only diverse organs, but also causes
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and capillaries [15]. In addition, patients with HES pre-
sent with coagulation abnormalities, especially dissemi-
nated intravascular coagulation (DIC), possibly due to
this thrombotic tendency [9,14,16-18]. However, the
mechanism of HES-derived coagulation abnormality is
not fully understood.
Case presentation
A 77-year-old Japanese man presented to the out-
patient department of our hospital (day one) with hema-
turia (42,000 red blood cells/μL) and a hematoma under
the jaw. He had anemia (hemoglobin (Hb) 9.3 g/dL),
and a remarkable eosinophilia (2600 cells/μL; 32% of
white blood cells) (Figure 1a). He had a history of minor
bronchial asthma, which had been treated with an
inhaled glucocorticoid and an anticholinergic. His medi-
cal records also showed a history of hypereosinophilia
five years earlier, when he developed femoral artery
occlusion. He was prescribed warfarin 2 mg/day after
the associated bypass surgery. In spite of this history,
vascular risk factors (diabetes mellitus, hypertension,
and hyperlipidemia) were absent. At presentation, renal
damage (b2-macroglobulin 9.5 mg/L, normal range 0.9
to 1.9 mg/L) was recognized. High levels of IgG and IgE
(Figure 1g) were also noted. IgA (90 mg/dL) and IgM
(36 mg/dL) were within normal ranges. While his plate-
let count (169,000 cells/μL) and bleeding time (one and
a half minutes, normal range one to three minutes)
were normal, coagulation times were remarkably pro-
longed: the activated partial thromboplastin time
(APTT) was 68 seconds (normal: 25 to 40 seconds) and
the prothrombin time-international normalized ratio
(PT-INR) was 1.65 (Figure 1c,d). Since hematuria and
hematoma were assumed to be due to this coagulopathy,
warfarin was stopped.
We considered bronchial asthma, eosinophilic pneu-
monia, Churg-Strauss syndrome (CSS), malignancies
[19], parasitic infections, adrenal insufficiency, and HES
as differential diagnoses to explain this eosinophilia.
However, his minor bronchial asthma did not explain
the high level of eosinophilia. Since a computed tomo-
graphy (CT) scan detected no abnormalities in the
lungs, eosinophilic pneumonia was excluded. Among six
diagnostic criteria for CSS, only asthma and eosinophilia
were fulfilled [20]. In addition, tests for anti-neutrophil
cytoplasmic antibodies (ANCAs) were negative. There-
fore, CSS was unlikely. Tumor markers were measured
(carcinoembryonic antigen (CEA), squamous cell carci-
noma (SCC), a-fetoprotein (AFP), and protein induced
by vitamin K absence 2 (PIVKA2)) and M-protein find-
ings were all negative. There were no parasitic eggs or
larvae in his stool, and results of sera anti-Aspergillus
antibody tests were negative. His cortisol level was
within the normal range on repeated measurements;
hence, adrenal insufficiency was considered unlikely.
Based on these results, HES remained as the most likely
diagnosis. To categorize the HES, monoclonality in the
T cell receptor (TCR) was examined by polymerase
chain reaction (PCR) [21] (Mitsubishi Medience, Tokyo,
Japan), using peripheral blood and bone marrow aspi-
rate. Subsequently, in both samples, TCR monoclonality
was detected in b, g, and δ chains (Table 1). This finding
supported the diagnosis of L-HES. Consistent with this
diagnosis, multiple enlarged lymph nodes near the
abdominal aorta were detected on CT scan (Figure 2).
In contrast, no chromosome abnormality was detected
in the bone marrow aspirates. In addition, fluorescence
in situ hybridization (FISH) analysis of peripheral blood
and bone marrow aspirates did not detect 4q12 translo-
cation, the most frequent translocation associated with
M-HES. Therefore, M-HES was less likely [2]. Collec-
tively, these findings pointed to a diagnosis of L-HES.
After warfarin was stopped from day one, his PT-INR
steadily normalized (Figure 1d). However, APTT contin-
ued to be prolonged (Figure 1c). Although our patient
tested positive for anti-hepatitis B core (HBc) and anti-
hepatitis C virus (HCV) antibodies, hepatitis B surface
(HBs) antigen, hepatitis B virus (HBV) DNA and HCV
RNA were all undetectable. Transaminases were consis-
tently within the normal range. Ultrasonography, CT,
and MRI scans did not detect any abnormality in the
liver. Hence, the liver was not the source of the pro-
longed APTT. Other causes of a coagulation abnormal-
ity (such as protein C and/or S deficiencies, systemic
lupus erythematosus, and anti-phospholipid antibody
syndrome) were excluded (data not shown). Although
the possibility of DIC was suggested (fibrin degradation
products (FDP) 18 μg/mL, D-dimer 7.4 μg/mL, anti-
thrombin III 66%, platelet count 117,000 cells/μL), ultra-
sonography detected no thrombus in the heart or veins/
arteries of the lower limbs. Taken together, the findings
suggested the prolonged APTT in our patient most
likely originated from his HES.
On day 28, our patient developed a subcutaneous
hematoma in his hip, which spread rapidly to the thighs,
and he was admitted to our hospital. His APTT was
further prolonged (83 seconds; Figure 1c). Hematomas
appeared on his trunk and upper limbs. His oral mucosa
and a scar in his ear began to bleed. Although a large
amount of fresh frozen plasma and red blood cells were
infused between days 31 and 34, his APTT reached a
high of 93 seconds on day 36, and the hemoglobin level
decreased to 7.9 g/dL (Figure 1c,f). On day 36, predniso-
lone was started at 60 mg/day (Figure 1b). His periph-
eral eosinophils decreased quickly (Figure 1a). The
APTT and platelet count gradually normalized (Figure
1c,e), while bleeding, subcutaneous hematomas,
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Renal damage improved (b2-macroglobulin decreased to
3.4 mg/L). A CT scan revealed that the lymph nodes
around the abdominal aorta had shrunk to a normal
size (data not shown). His g-globulinemia normalized
(Figure 1g). He was discharged on day 55. Prednisolone
was continuously tapered in the out-patient setting (Fig-
ure 1b).
On day 122, when the dose of prednisolone was down
to 3 mg/day, a subcutaneous hematoma developed in
his thigh. Although his eosinophil count was normal at
64 cells/μL (0.4% of the total white blood cells), his
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Figure 1 Temporal profile of the biological manifestations and treatment of our patient. (a) Eosinophil count, (b) prednisolone
(intravenous and oral), (c) activated partial thromboplastin time, (d) prothrombin time-international normalized ratio (PT-INR), (e) platelet count,
(f) hemoglobin level, (g) IgG, IgG4 (mg/dL) and IgE (IU/mL), and (h) anticoagulant to factor VIII, are plotted above the time axis.
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was admitted to our hospital again, where prednisolone
was raised to 40 mg/day (Figure 1b). Since his APTT
then normalized and hematoma diminished steadily, he
was discharged on day 141. To date, he has been kept
on prednisolone at 10 mg/day, with no further relapses
of coagulopathy or peripheral hypereosinophilia.
To investigate the prolonged APTT, coagulation fac-
tors V to XII were measured. Consequently, the activ-
ity of factor VIII was markedly reduced: 4% on day
122 (the day of relapse onset). Other factors were all
within normal ranges (data not shown). To examine
the pathogenesis of the coagulopathy, we preserved
our patient’s sera (at -80°C) taken after day 34. Control
sera were also obtained from 10 healthy individuals
( a g e s2 9t o5 9y e a r so l d ,f i v em e n ,f i v ew o m e n ) .
Written informed consent was obtained from all indi-
viduals. The research protocol was approved by the
committee for clinical ethics of Yao Tokushukai Gen-
eral Hospital. Circulating anticoagulant against factor
VIII was evaluated in the preserved sera by using the
Bethesda assay. As a result, our patient’s anticoagulant
level was found to be elevated during both the initial
and relapse episodes: 47 BU/mL on day 36, 4 BU/mL
on day 124 (Figure 1h), while anticoagulant was not
detected in any of the control sera. Furthermore, the
result of a cross-mixing test conducted on day 122 was
not inconsistent with acquired hemophilia (that is,
acquisition of anticoagulant) (Figure 3). Our patient
and his parents had no history of bleeding abnormal-
ities, which excluded hereditary hemophilia. Therefore,
acquired hemophilia was the most likely diagnosis.
Other than anticoagulant against factor VIII, all the
autoantibodies examined (including anti-nuclear, anti-
Sjögren’s syndrome A/B (SS-A/B), anti-thyroglobulin,
anti-thyroid peroxidase, and anti-DNA antibodies)
showed normal values.
To illustrate the immunological dynamics in our
patient, 15 cytokines in the sera were measured by using
a Milliplex assay (Millipore, Billerica, MA, USA) (Figure
4). To examine the possible involvement of IgG4-related
disease (IgG4RD), a newly recognized disease entity
[22], we measured IgG4 in the preserved serum. IgG4
showed a disproportionately high value (Figure 1g). For
example, on day 36, IgG4 was 2070 mg/dL (normal
range 4.8 to 105 mg/dL), which constituted 48% of the
total IgG (normal value < 7%).
Table 1 Monoclonalities detected by polymerase chain
reaction (PCR) in the T-cell receptor genes
Chain Region to which PCR was
applied
Bone
marrow
Peripheral
blood
b
Chain
Vb/Jb1,2 Positive Positive
Vb/Jb2 Positive Positive
Db/Jb Positive Positive
g
Chain
Vg If, Vg10/Jg Positive Positive
Vg 9, Vg11/Jg Positive Positive
δ
Chain
Vδ/Jδ Positive Marginal
Positive: monoclonality was detected. Marginal: the peak of PCR was
noticeable but its height was lower than the positive control. The
methodology is described in detail in [21].
Figure 2 Enlarged lymph nodes near the abdominal aorta at
the onset of illness. The enlarged lymph nodes are indicated.
Percentage of normal plasma
APTT (second)
IPVST
IPVS
Figure 3 Mixing test. The activated partial thromboplastin time
(APTT) was measured on day 122 with our patient’s plasma mixed
with normal plasma collected from healthy individuals, in various
proportions. APTT was measured immediately after the mixing (solid
line) and after a two-hour incubation at 37°C (dashed line). The
incubation prolonged APTT as compared to no incubation,
suggesting the presence of a circulating anticoagulant.
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Figure 4 Temporal profile of cytokines in our patient’ss e r a . The following 15 cytokines were measured in the sera taken after day 34:
interleukin (IL)-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-13, IL-15, IL-17, eotaxin-1, eotaxin-3, granulocyte colony stimulating factor (G-CSF), granulocyte-
macrophage colony stimulating factor (GM-CSF), tumor necrosis factor a (TNFa), and interferon g (IFNg). The dashed line in the each panel
represents the upper limit of the 95% confidence interval (95% CI) estimated from the healthy controls. Day 36 (when prednisolone was started
at 60 mg/day) and day 122 (when prednisolone was raised from 3 mg/day to 40 mg/day) are specifically labeled on the time axis. IL-3, IL-4, IL-
17, and IFNg, which were consistently within the 95% CI of controls, were thus omitted.
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We report a case of a patient with L-HES who manifested
with a coagulation abnormality. Glucocorticoids effec-
tively suppressed hypereosinophilia and corrected the
coagulation abnormality. However, excessive subsequent
tapering of the glucocorticoid brought about a relapse of
the coagulation abnormality, but not the eosinophilia.
It has been reported that HES can manifest with
thrombotic tendency. Our patient had developed
femoral artery occlusion, a frequent manifestation of
HES-induced thrombosis, five years prior to the episode
reported here. The thrombotic tendency had been con-
trolled effectively by warfarin. In the episode reported
here, factor VIII activity was remarkably decreased,
which was most likely due to acquired hemophilia.
Hypereosinophilia complicated with acquired hemophi-
lia has been reported only once previously in the litera-
ture [23]. In our patient, DIC, a frequent complication
of HES [9,14,16-18], possibly exacerbated the bleeding
tendency. These findings remain to be generalized to
other cases of HES-derived coagulopathy.
Our patient’s case, featuring an extremely high value
of IgG4, is likely to be an example of IgG4RD. IgG4RD,
first reported in 1993 [24], is characterized by elevated
serum IgG4 and/or tissue infiltration by IgG4+ plasma
cells [25,26]. IgG4RD has been recognized as a systemic
illness which affects numerous organs including lymph
nodes [24], pancreas [25], salivary gland [24,26], retro-
peritoneum [27], and kidney [28]. Its pathogenesis, how-
ever, remains to be elucidated [22]. IgG4RD has been
often associated with eosinophilia [29-31], and responds
well to glucocorticoid [22]. These characteristics are
consistent with our patient, supporting the diagnosis of
IgG4RD in this case. To the best of our knowledge, the
presented case is the first reported example in which L-
HES and IgG4RD have overlapped.
The cytokines measured in our patient’ss e r ac a nb e
classified into three groups in relation to the illness (Figure
4). First, tumor necrosis factor a (TNFa), interleukin (IL)-
5, and eotaxin-3 increased to very high levels immediately
before the first episode, and decreased to low levels after
the glucocorticoid was started on day 36. Therefore, these
cytokines were correlated with eosinophilia. Second, IL-10
was present at very high levels until glucocorticoid was
started on day 36, and peaked again at the onset of relapse.
Hence, IL-10 exhibited a strong correlation with pro-
longed APTT and anticoagulant to factor VIII. Third,
other cytokines in Figure 3 rose to high levels immediately
after day 36. These peaks may possibly be reactions to
substances released from dying eosinophils [9,18]. Among
the cytokines in this group, granulocyte colony stimulating
factor (G-CSF) and eotaxin-1 showed second elevations in
the relapse phase, suggesting heterogeneity within this
group. The roles of these cytokines in the pathogenesis are
difficult to explain. Collectively, TNFa, IL-5, and eotaxin-3
appeared to play an important role in generating periph-
eral hypereosinophilia, while IL-10 was most closely corre-
lated with prolonged APTT and anticoagulant. Indeed,
eosinophilic diseases have been associated with TNFa
[32,33], IL-5 [34], IL-10 [35], and eotaxin-3 [36,37], while
IL-10 was overexpressed in IgG4RD [38,39]. The causal
relationship between these cytokines, eosinophilia, IgG4,
and clinical manifestations remains to be elucidated.
Conclusions
To the best of our knowledge, this is the first case of L-
HES overlapped with IgG4RD, and the second reported
case of hypereosinophilic disease complicated by acquired
hemophilia. Furthermore, this is the first case of L-HES or
IgG4RD in which the cytokine profile was described dur-
ing the phases of onset and relapse. Although the clinical
manifestation (that is, coagulopathy) presented twice (in
the first episode and in the relapse), the underlying immu-
nological profiles were dissimilar between these two peri-
ods. These findings imply that the interaction between
HES and IgG4RD is a complex process.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
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